Business Context and Reporting Period
This Form 8-K Current Report was filed by Assembly Biosciences, Inc. on December 2, 2020. The filing addresses a strategic pivot by the Board of Directors to wind down the Company's Microbiome program on or around January 31, 2021, to prioritize resources for its pipeline of novel core inhibitors targeting chronic hepatitis B virus infection.
Key Financial Metrics and Material Changes
The filing does not provide standard financial statements (revenue, profit, cash flow, or margins) as it is a current report on specific events. However, it discloses the following material financial impacts related to the program wind-down:
- Estimated Charges: The Company anticipates incurring charges between $5.8 million and $7.9 million.
- Charge Composition:
- Employee-related costs: $4.5 million to $5.1 million.
- Remaining lease and other contract obligations: $1.3 million to $2.8 million.
- Cash Impact: The cash component of the charge is expected to be approximately $5.7 million to $7.2 million.
- Timing: Charges are expected to be incurred over the fourth quarter of 2020 and the first quarter of 2021.
Material Change Context: This decision follows the termination of a collaboration agreement with Allergan Pharmaceuticals International Limited (acquired by AbbVie, Inc.) and a failed strategic outreach process to find a buyer for the Microbiome program. The filing explicitly states the decision is not based on efficacy, safety, or other data related to the program.
Management Commentary, Risks, and Corporate Governance
Management Commentary: The Board determined that the breadth and duration of strategic outreach, combined with the financial and internal resources required to continue the Microbiome program, necessitated the wind-down. The Company will continue to review potential strategic options for the program in the interim but expects to proceed with the wind-down absent an alternative.
Corporate Governance Changes: On December 2, 2020, the Board accepted the resignations of Directors Helen S. Kim and Alan J. Lewis, Ph.D., effective December 31, 2020. Ms. Kim cited a change in professional circumstances and increased work commitments, while Dr. Lewis cited personal reasons. The Company stated neither resignation was due to any disagreement with the Company regarding strategies, operations, or policies.
Risks and Contingencies: The Company notes that its cost estimates are subject to assumptions and actual results may differ. Additionally, the Company may incur additional costs not currently contemplated due to events associated with the wind-down.
Investor Verification Checklist
- Verify the exact timing and final amount of the $5.8 million to $7.9 million charge in the Q4 2020 and Q1 2021 financial reports.
- Confirm the status of the Microbiome program wind-down and whether any strategic alternatives were identified after the filing date.
- Review the Company's updated cash burn rate and runway following the anticipated cash outflow of $5.7 million to $7.2 million.
- Monitor the progress of the core inhibitor pipeline for chronic hepatitis B as the new primary focus of the Company.
- Check for the appointment of new directors to replace Helen S. Kim and Alan J. Lewis, Ph.D.